Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Congress

Trump Signs FDA User Fee Agreement into Law; PhRMA and BIO Applaud the Move

Washington, DC, August 21, 2017 — President Donald J. Trump on Friday signed into law a funding package for the Food and Drug Administration (FDA) that also takes steps to lower drug prices.

The FDA Reauthorization Act (FDARA) of 2017 reauthorizes a program in which drug and medical device makers pay the FDA a fee for every new product application.  The agency uses those funds to hire more people and speed up approvals.

The user fee program must be reauthorized every five years. The current program expires at the end of September, and if it hadn’t been signed into law before then, the agency would have had to lay off workers. Continue reading

U.S. Senate’s ‘Right to Try’ Bill Could Face Slower Action in House

Washington, DC, August 15, 2017Roll Call reports that a U.S. Senate-passed “right to try” bill that is intended to help dying patients access experimental drugs, which have yet to receive Food and Drug Administration (FDA), likely will face lengthier deliberations in the U.S. House of Representatives.

While the Senate fast-tracked the bill on August 3, the House will likely subject it to a hearing and markup before bringing it up to a vote, according to congressional aides and a lobbyist.

The bill would reduce some of the paperwork involved in getting access to experimental treatments, and would offer protections to the drug companies who choose to make drugs available outside of a clinical trial. Continue reading

After 2-Year Hiatus, 2.3 Percent Medical Device Tax Could Be Reinstated on January 1; Industry Launches Campaign

Washington, DC, August 15, 2017 — Bob Salsberg reports in The Washington Post that the industry that makes medical devices from artificial hips to miniature pumps for IV drips is looking for a fallback plan to permanently repeal a widely reviled sales tax that almost met its end in Republicans’ health care legislation.

The 2.3 percent medical device excise tax — one of several taxes and fees in the Affordable Care Act that pay for expanded insurance coverage — has been the subject of ferocious lobbying by manufacturers seeking its permanent death.

Yet for now it’s on track to be reinstated on Jan. 1 after a two-year hiatus, leaving industry leaders worried it will hurt employment and stifle development of innovative, even lifesaving products. Continue reading

Kaiser Family Foundation Poll: 78 Percent Say Trump Should Try to Make Obamacare Work

Washington, DC, August 11, 2017 — Jessie Hellman reports in The Hill that 78 percent of Americans say President Trump and his administration should do what they can to make Obamacare work, according to a new Kaiser Family Foundation Poll released today.

That includes 95 percent of Democrats, 80 percent of independents and even a majority of Republicans at 52 percent, according to the.

Seventeen percent, though, think Trump should make the law fail so it can be replaced later. Continue reading

Medical Device Group Launches Ad Campaign to Repeal Obamacare’s 2.3 Percent Excise Tax

Washington, DC, August 10, 2017 — Peter Sullivan reports in The Hill that the Advanced Medical Technology Association (AdvaMed) is launching a new advertising campaign to push lawmakers to repeal Obamacare’s tax on medical devices.

AdvaMed will be running the digital and social media ads in 15 states this month, pushing lawmakers to repeal the medical device tax when they return from recess in September.  Continue reading

Trump Will Sign FDA User Fee Reauthorization Bill, Ending Threat of Agency Layoffs; Industry Praises Move

Washington, DC, August 8, 2017 — Zachary Brennan reported on Endpoints News that President Donald J. Trump will sign bipartisan legislation, passed by the U.S. Senate on August 3, that reauthorize the Food and Drug Administration (FDA) user fee programs for prescription drugs, generic drugs, medical devices and biosimilars for the next five years.

A spokesman for President Trump told Focus, “The President will sign this bill, but we look forward to working with Congress to address further negotiations.”

The Senate’s passage of the House bill by a vote of 94-1 — Bernie Sanders (D-VT) was the only vote against — came more than two years after negotiations on the reauthorization began. Continue reading

U.S. Senate Passes Bill to Improve Cancer Drugs for Children

Washington, DC, August 7, 2017 — Ledyard King reports in USA Today that, until now, drug companies have been free to decide whether to pursue treatments for pediatric cancers as part of their work on adult cancers.

They won’t have much choice going forward.

The Senate on August 3 overwhelmingly passed legislation requiring the pharmaceutical industry to expend more resources on treatment for childhood cancers. Continue reading

Quinnipiac National Poll: Voters Disapprove 5-1 of GOP Handling of Health Care

Washington, DC, August 4, 2017 — More than half of Republicans in a Quinnipiac University poll released on Thursday do not approve of the way their party has handled healthcare in Congress.

Sixty percent of Republicans said they disapprove, while only 32 percent of Republicans said they approve.

American voters as a whole also voiced their disapproval with Republican efforts, with 80 percent saying they disapprove.  Fifteen percent said they approve. Continue reading

U.S. Senate Passes ‘Right to Try’ Bill to Help Terminally Ill Patients Access Experimental Drugs

Washington, DC, August 3, 2017 — Laurie McGinley reports in The Washington Post that the United States Senate today passed by unanimous consent a measure designed to make it easier for terminally ill patients to get access to experimental treatments without oversight from the Food and Drug Administration.

The “right-to-try” legislation has been championed by the libertarian Goldwater Institute, which has worked to pass similar legislation in 37 states.

The federal version, now headed to the House, would bar the government from blocking patients from getting access to medications that have undergone only preliminary testing in humans. Continue reading

NIH to Walk Away from $16 Million of NFL Gift for Brain Research

Washington, DC, July 31, 2017The Los Angeles Times reports that, five years ago, four months after the suicide of legendary linebacker Junior Seau, the National Football League donated $30 million to the National Institutes of Health (NIH) for brain research.

At the time, the league said its “unrestricted gift” was the largest donation in its history and would help fund a new Sports and Health Research Program to be conducted in collaboration with institutes and centers at the NIH. Continue reading